Business interests lobby the US government to bully developing countries into changing their economic laws and practices so as to favor the commercial interests of multinationals. Unfortunately this can come at the expense of health, education and other sensitive public interests. We are countering the corporations’ analysis and arguing for a more independent US government policymaking that defends global health.
For example, I testified at a recent hearing by the US Trade Representative, criticizing the US Government’s Special 301 “Watch List.” At stake is India’s key role helping facilitate global access to affordable medicines. Read more here.
We co-authored this piece in The Huffington Post with Representative Raul Grijalva, Co-Chair of the Congressional Progressive Caucus. It concerns a US Government policy that would compromise access to medicines in developing countries. Read more: http://huff.to/1e82A0W.
October 2013: Click here for an article I wrote about our access to medicines work in Public Citizen News. “By providing analysis and building relationships to influence what goes on inside the secretive Trans-Pacific negotiations, Public Citizen’s Global Access to Medicines Program has transformed key elements of the discussion.”
Sometimes the influence of money in politics gets in the way. For the past three years we have been monitoring secretive trade negotiations which could compromise health interests. Last week, New York’s mayor Michael Bloomberg published an editorial criticizing the harm these negotiations could do to efforts to curb youth smoking and tobacco-related deaths.
From leaked documents and relationships with negotiators, we know that unfortunately the US government has proposed some very harmful measures. Together with Judit Rius Sanjuan of MSF / Doctors Without Borders I wrote this letter, published in the New York Times, online and print edition.
By Sarah Boseley as originally published in The Guardian The multinational drug company Abbott is being targeted by health campaigners in a number of countries in a concerted campaign to try to break its monopoly on a valuable AIDS drug called Kaletra. …
Public Citizen in the USA is leading the charge, but campaigners in Brazil, India, Vietnam, Indonesia, Colombia, Thailand, the Netherlands and elsewhere are all taking action – mostly by challenging Abbott’s monopoly in their own legal systems. One company is being challenged, over one drug, but Public Citizen believes the orchestrated attack has greater significance —>Continue reading
All across the country, college students are being denied the right to vote in their adopted hometowns — effectively banning them from local politics.
Except their vote isn’t welcome in Brunswick, Maine. Or in Prairie View, Texas. Or, as a matter of fact, in Utica, New York. All of these college towns — and many others — have local statutes that limit students from establishing residency and registering to vote. Continue reading →
works with partners worldwide to improve health outcomes and save lives, through use of pharmaceutical cost-lowering measures including generic competition. We help civil society groups and public agencies overcome patent-based and other drug monopolies. We assess new developments in policy and law, and work with coalition partners to promote game-changing ideas that advance pharmaceutical access and innovation simultaneously. Read more.
International Professional Partnerships for Sierra Leone (IPPSL) brings skilled, cross-culturally experienced professionals from various countries to work in the government of Sierra Leone under the direction of public officials and assist in Sierra Leone’s hopeful renaissance. Continue reading →